Primary Hyperoxaluria Type 1
Invitae and Alnylam have partnered to offer genetic testing at no charge for individuals who may carry a gene mutation known to be associated with primary hyperoxaluria type 1.
The Alnylam Act program was created to potentially enable diagnosis and to provide genetic counseling to help people make more informed decisions about their health.
The Detect Hereditary Prostate Cancer genetic testing program provides sponsored, no-charge genetic testing and counseling for individuals diagnosed with prostate cancer stage II and above.
Prostate cancer is the leading cancer in males. An estimated 174,000 patients are newly diagnosed each year in the U.S. The Detect Hereditary Prostate Cancer program is designed to determine the germline genetic etiology of prostate cancer to evaluate precision medical and surgical treatment options.
